During the recent session, Hepion Pharmaceuticals Inc (NASDAQ:HEPA)’s traded shares were 0.77 million, with the beta value of the company hitting 1.70. At the last check today, the stock’s price was $0.60, reflecting an intraday loss of -12.26% or -$0.09. The 52-week high for the HEPA share is $144.99, that puts it down -24065.0 from that peak though still a striking 8.33% gain since the share price plummeted to a 52-week low of $0.55. The company’s market capitalization is $0.65M, and the average intraday trading volume over the past 10 days was 3.5 million shares, and the average trade volume was 1.06 million shares over the past three months.
Hepion Pharmaceuticals Inc (HEPA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 3.00. HEPA has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.
Hepion Pharmaceuticals Inc (NASDAQ:HEPA) trade information
Hepion Pharmaceuticals Inc (HEPA) registered a -12.26% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -12.26% in intraday trading to $0.60, hitting a weekly high. The stock’s 5-day price performance is -27.50%, and it has moved by -92.29% in 30 days. Based on these gigs, the overall price performance for the year is -99.47%. The short interest in Hepion Pharmaceuticals Inc (NASDAQ:HEPA) is 0.16 million shares and it means that shorts have 0.34 day(s) to cover.
The consensus price target of analysts on Wall Street is $70, which implies an increase of 99.14% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $70 and $70 respectively. As a result, HEPA is trading at a discount of -11566.67% off the target high and -11566.67% off the low.
HEPA Dividends
Hepion Pharmaceuticals Inc is due to release its next quarterly earnings on 2024-Apr-15. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Hepion Pharmaceuticals Inc (NASDAQ:HEPA)’s Major holders
Hepion Pharmaceuticals Inc insiders own 1.96% of total outstanding shares while institutional holders control 1.48%, with the float percentage being 1.51%.
Also, the Mutual Funds coming in first place with the largest holdings of Hepion Pharmaceuticals Inc (HEPA) shares are VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund. Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund owns about 978.0 shares. This amounts to just over 0.00 percent of the company’s overall shares, with a $586.0 market value. The same data shows that the other fund manager holds slightly less at 631.0, or about 0.00% of the stock, which is worth about $378.0.
